“…The FDA and the Drug Enforcement Agency recognize that specific animal models are particularly informative when assessing abuse liability (Food and Drug Administration, 2010). The following animal models and techniques would be particularly useful in evaluating effects of reducing levels of nicotine: (a) Drug self-administration models that provide estimates of threshold reinforcing nicotine doses in adolescents and adults and factors that moderate them; (b) demand curve analysis and growthcurve analysis that provide quantitative techniques to facilitate detection of factors that moderate reduction and acquisition of self-administration, respectively (Greenwald & Hursh, 2006;Hursh, Galuska, Winger, & Woods, 2005;Hursh & Silberberg, 2008;Lanza, Donny, Collins, & Balster, 2004); (c) drug discrimination models that can be used to screen understudied or novel constituents for their own abuse potential or capability of enhancing nicotine's effects (Smith & Stolerman, 2009); (d) withdrawal models that allow for further delineation of the mechanisms underlying possible adverse consequences of reduction (e.g., Harris, Pentel, Burroughs, Staley, & Lesage, 2011); and (e) methods incorporating tobacco smoke, tobacco extracts, or other known tobacco constituents to facilitate research on the aggregate contribution of constituents to abuse liability (e.g., Harris, Stepanov, Pentel, & Lesage, 2012).…”